Custom Array development
Using our patent pending technology Quansys is able to design and develop sensitive and specific multiplex arrays for use in a wide variety of applications. We provide a multiplex tool and with our partner’s content and specification, we can build a product to meet your research needs.
Our highly efficient system allows us to keep costs low and assay accuracy high. Using our Class 1000 clean room facility, we produce specialized multiplex elisa kits with lyophilized reagents for long-term stability. We can also develop controls used for standard curve generation. Costs to develop a custom elisa array will vary depending on the availability of reagents, the types of biomarkers desired, and the time involved to develop, optimize, and validate the elisa array.
In developing a custom elisa array there are many steps involved. In order to better ensure the success of your elisa array development project we have divided the development process into phases.
Click here to see a few examples of the custom development process.
| Phase I—Feasibility | |
|---|---|
| • Antibody and antigen acquisition | • Determine cross reactivity |
| • Intra-assay precision | • Determine Sensitivity |
| • Standard curve generation | |
| Phase II—Development/Validation | |
| • Assay optimization | • Assay range optimization |
| • Pre/post lyophilization testing | • Sensitivity |
| • Precision: intra-, inter-, and lot-to-lot | • Recovery |
| • Linearity | • Edge effect and drift |
| • Production development | • Beta kit production |
| Phase III—Pilot Production | |
| • Production protocol implementation | • Update Q-View Software |
| • Performance and QC specifications | • Create manuals and COAs |
| • Estimate production costs | • Label design and development |
| • Produce first lot for customer use | • Develop shipping criteria |
Q-Plex Case Studies:
A selection of projects showcasing Quansys’ rapid and efficient array development services
Pre-Clinical Array
A biopharmaceutical company wanted to multiplex novel proteins that are indicators of target organ toxicity. Researchers had previously tested these proteins individual ELISAs or on other multiplex platforms. After a lack of success in other platforms, they decided that the Quansys Biosciences chemiluminescent technology—the Q-Plex™ Array—would be the preferred platform. Chemiluminescent ELISAs have been shown to be more sensitive than traditional colorimetric ELISAs, and there are no known endogenous luminescent chemicals as in fluorescent arrays; using Q-Plex™ was a logical choice. Using Q-Plex™ technology, the company rapidly screened their library of antibodies for cross reactivity and matched pair determination.
CRO-Cytokine Array
A contract research organization (CRO) in Texas was asked by its sponsor to evaluate cytokine responses for multiple cytokines. This request was made in the final two weeks of the study, and multiplex ELISA was the only option that allowed for completion of the testing on time. After consulting other suppliers and service providers who were not able to help in a timely manner, the CRO contacted Quansys Biosciences. Quansys was able to get an imaging system and testing kits to the CRO the following day. With a minimal amount of training from Quansys’ tech support personnel, the CRO was able to perform the assays and, most importantly, analyze the large amount of data included in their final report to the sponsor.
Pre-Clinical Pharma Array
A virtual pharmaceutical company approached Quansys Biosciences to devise assays that would help establish proof of concept that the pharmaceutical company required. This required Quansys to develop ELISAs that had not previously been developed anywhere else. Quansys was able to develop the required ELISAs in a multiplex platform covering multiple species and test the pharmaceutical company’s in vitro and in vivo samples in-house using Quansys’ sample testing services.
If you would be interested in having a custom ELISA Array or ELISA assay developed for your specific needs please contact us.
